Synergy Pharmaceuticals to Begin Trading on The NASDAQ Global Market


11.02.13 11:05
Meldung
 
(Nasdaq:SGYP), a developer of new drugs to treatgastrointestinal disorders and diseases, today announced that its common stockhas been approved for listing on The NASDAQ Global Market under the symbol'SGYP.' Trading on The NASDAQ Global Market is expected to commence on February12, 2013. The Company's units and warrants will continue to trade on The NASDAQCapital Market under the symbols 'SGYPU' and 'SGYPW,' respectively. About Synergy Pharmaceuticals Inc.Synergy is a biopharmaceutical company focused on the development of new drugsto treat gastrointestinal disorders and diseases. Synergy's lead proprietarydrug candidate, plecanatide, is a synthetic analog of the humangastrointestinal hormone uroguanylin, and functions by activating the guanylatecyclase C receptor on epithelial cells of the GI tract. Synergy completed apositive Phase I study of plecanatide in healthy volunteers, and positive PhaseIIa and Phase IIb/III clinical trials in patients with chronic idiopathicconstipation (CIC). Detailed positive findings from a recently completed PhaseIIb/III clinical trial will be presented at a major scientific meeting thisyear. Synergy is also developing plecanatide for the treatment of irritablebowel syndrome with constipation (IBS-C), having initiated the first trial inIBS-C patients in late 2012. Synergy's second GC-C agonist, SP-333, is inclinical development to treat inflammatory bowel diseases, and has justcompleted its first Phase I trial in healthy volunteers. More information isavailable at http://www.synergypharma.com. Media Contact: Janet Skidmore Office: 215-658-4915 Mobile: 215-429-2917 skidmorecomm@earthlink.net Investor Contact: Danielle Spangler The Trout Group synergy@troutgroup.com (646) 378-2924News Source: NASDAQ OMX11.02.2013 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG.The issuer is solely responsible for the content of this announcement.DGAP's Distribution Services include Regulatory Announcements,Financial/Corporate News and Press Releases.Media archive at www.dgap-medientreff.de and www.dgap.de--------------------------------- Language: EnglishCompany: Synergy Pharmaceuticals United StatesPhone: Fax: E-mail: Internet: ISIN: US8716393082WKN: End of Announcement DGAP News-Service ---------------------------------


 

Kurs- und weitere Informationen zum Thema:

Synergy Pharmaceuticals

Aktuelle Diskussionen zum Thema:

Int. Biotech-Aktie mit laufenden ... (30.07.15)

Aktuelle Nachrichten zum Unternehmen:


Alle Nachrichten zum Unternehmen

Aktuelle Analysen zu den Unternehmen:

Synergy Pharmaceuticals
Weitere Meldungen
 
12.02 Stimmrechtsanteile: LEG Imm.
12.02 Stimmrechtsanteile: LEG Imm.
12.02 Stimmrechtsanteile: LEG Imm.
12.02 Stimmrechtsanteile: LEG Imm.
12.02 Stimmrechtsanteile: LEG Imm.
12.02 Limelight Appoints George V.
12.02 World Markets AG : Jahres.
12.02 Zwischenmitteilung: LS telco.
12.02 Stimmrechtsanteile: KUKA A.
12.02 Zulassungsfolgepflichten: Aa.
12.02 Zulassungsfolgepflichten: QIA.
12.02 Stimmrechtsanteile: Bertrandt.
12.02 Proto Resources & Investme.
12.02 Finanzbericht: ZEAG Energie.
12.02 Zwischenmitteilung: Eisen- u.
12.02 Universal Bioenergy's NDR E.
12.02 Zwischenmitteilung: SCHULE.
12.02 KROMI Logistik AG baut U.
11.02 Stimmrechtsanteile: ESTAVI.
11.02 Stimmrechtsanteile: ESTAVI.
11.02 Stimmrechtsanteile: ESTAVI.
11.02 Directors' Dealings: Rofin-Sin.
11.02 Cham Paper Group Holding .
11.02 Zwischenmitteilung: MAGNA.
11.02 Stimmrechtsanteile: Francoty.
11.02 Finanzbericht: Andreae-Noris .
11.02 Deutsche Rohstoff AG: Tek.
11.02 Synergy Pharmaceuticals to .
11.02 Finanzbericht: Sektkellerei Sc.
11.02 Dresdner Factoring veröffent.


Umfrage
 
Welche Social Networks nutzen Sie meistens?
Facebook
keine
Twitter
Xing
Linked in
Youtube
myspace
Google+
Wikipedia
andere


Stimmen: 8075 , Ergebnis


Kurssuche
Status: nicht eingeloggt

Registrieren | Passwort vergessen?
 
 
Im Bereich Nachrichten:
Nokia: Da ist das Kaufsignal!
Experte: Stefan Hofmann, STOCK-WORLD
Kolumnen
HeidelbergCement und ...
Feingold-Research, (16:00)
Experte: Feingold-Research,
DAX: Schleppender ...
IG Markets, (15:53)
Experte: IG Markets,
Continental: weiter nach ...
trading notes future, (15:45)
Experte: trading notes future,
FED ohne klaren Kurs, ...
Jens Klatt, Chefanalyst von DailyFX (15:33)
Experte: Jens Klatt, Chefanalyst von DailyFX
Merck: Anhebung der ...
Robert Sasse, (15:27)
Experte: Robert Sasse,
Im Fokus: Deutsche Bank
Dominik Auricht, HypoVereinsbank onema. (15:19)
Experte: Dominik Auricht, HypoVereinsbank onemarkets
Equitas Resources nimmt ...
Björn Junker, GOLDINVEST.de (15:17)
Experte: Björn Junker, GOLDINVEST.de
Positive ...
Cornelia Frey, Börse Stuttgart AG (15:12)
Experte: Cornelia Frey, Börse Stuttgart AG
Wetterphänomen El Nino ...
CMC Markets, (14:48)
Experte: CMC Markets,
Nokia: Da ist das ...
Stefan Hofmann, STOCK-WORLD (14:18)
Experte: Stefan Hofmann, STOCK-WORLD
LVMH - Ausgezeichnetes ...
DZ BANK, (14:04)
Experte: DZ BANK,
Nordex - Sell on good ...
Robert Schröder, Elliott-Waves.com (14:04)
Experte: Robert Schröder, Elliott-Waves.com
Niquet's World
Neues vom Portal
 
Leitfaden zur erfolgreichen Geldanlage
Letzte Börsen-Meldung
 
Letzte Börsen-Analyse
 
Top-Klicks News
 
Top-Klicks Analysen